Cart
sales@molnova.com
BIBO 3304
CAS No. 191868-14-1
BIBO 3304( BIBO3304 )
Catalog No. M13008 CAS No. 191868-14-1
BIBO 3304 is a potent, selective, nonpeptide neuropeptide Y Y1 receptor antagonist with IC50 of 0.38 and 0.72 nM for human and the rat Y1 receptor, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 133 | In Stock |
|
| 5MG | 210 | In Stock |
|
| 10MG | 371 | In Stock |
|
| 25MG | 617 | In Stock |
|
| 50MG | 879 | In Stock |
|
| 100MG | 1188 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBIBO 3304
-
NoteResearch use only, not for human use.
-
Brief DescriptionBIBO 3304 is a potent, selective, nonpeptide neuropeptide Y Y1 receptor antagonist with IC50 of 0.38 and 0.72 nM for human and the rat Y1 receptor, respectively.
-
DescriptionBIBO 3304 is a potent, selective, nonpeptide neuropeptide Y Y1 receptor antagonist with IC50 of 0.38 and 0.72 nM for human and the rat Y1 receptor, respectively; shows low affinity for the human Y2 receptor, human and rat Y4 receptor, human and rat Y5 receptor (IC50>1,000 nM); inhibits the feeding response induced by 1 mg NPY in mice, also completely abolishes PYY-induced inhibition of insulin release in vivo.Obesity Discontinued(In Vivo):BIBO3304 TFA (30 μg; bilateral paraventricular nucleus injection) attenuates the hyperphagia following fasting.BIBO3304 TFA (15-60 μg) dose-dependently inhibits the feeding reponse mediated by 1 μg NPY.BIBO3304 TFA (0.5 μM; p.o.) significantly increases serum insulin levels.
-
In Vitro——
-
In VivoBIBO3304 TFA (30 μg; bilateral paraventricular nucleus injection) attenuates the hyperphagia following fasting.BIBO3304 TFA (15-60 μg) dose-dependently inhibits the feeding reponse mediated by 1 μg NPY.BIBO3304 TFA (0.5?μM; p.o.) significantly increases serum insulin levels. Animal Model:Adult male Chbb:Thom rats weighing between 300 and 340 g Dosage:30 μg Administration:bilateral paraventricular nucleus injection Result:Attenuated the hyperphagia following fasting, especially during the first 2 h of refeeding.Animal Model:7-week-old C57BL/6JAusb mice Dosage:0.5?μM Administration:p.o.Result:Significantly increased serum insulin levels.
-
SynonymsBIBO3304
-
PathwayGPCR/G Protein
-
TargetNeuropeptide Y Receptor
-
RecptorNeuropeptide Y Receptor
-
Research AreaMetabolic Disease
-
IndicationObesity
Chemical Information
-
CAS Number191868-14-1
-
Formula Weight643.668
-
Molecular FormulaC31H36F3N7O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (155.36 mM)
-
SMILESC1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)NC(CCCN=C(N)N)C(=O)NCC3=CC=C(C=C3)CNC(=O)N
-
Chemical Name(R)-2-(2,2-diphenylacetamido)-5-guanidino-N-(4-(ureidomethyl)benzyl)pentanamide 2,2,2-trifluoroacetate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
M40
Potent, non-selective galanin receptor antagonist (Ki values are 1.82 and 5.1 nM at GAL1 and GAL2 respectively) that inhibits galanin (1-29) binding in rat brain in vitro (IC50 = 3 - 15 nM). Attenuates the antidepressant effects of fluoxetine and blocks galanin-induced food intake in vivo. Also exhibits weak partial agonist activity at peripheral GAL2 receptors at doses > 100 nM.
-
Galanin (1-29) (rat,...
Non-selective galanin receptor agonist (Ki values are 0.98, 1.48 and 1.47 nM for GAL1, GAL2 and GAL3 respectively). Anticonvulsant; prevents the occurrence of full kindled seizures in rats.
-
Galanin (1-30), huma...
Galanin (1-30), human is a 30-amino acid neuropeptide, and acts as an agonist of GalR1 and GalR2 receptors, with Kis of both 1 nM. Endogenous peptide with multiple endocrine, metabolic and behavioral effects. Has been shown to have an action on intestinal smooth muscle, insulin and somatostatin release, and synaptic neurotransmission.
